ACADEMIC DEGREES 1990 PhD, University of Sydney 1985 BSc (Hons) (Biochemistry), University of NSW ACADEMIC AND RESEARCH APPOINTMENTS 2015 - Professor, School of Biological Sciences, University of Wollongong 2014 - Illawarra Lead and CI CONCERT Translational Cancer Research Centre 2013 – Visiting Research Fellow, Institute of Genetics and Biophysics, National Research Council, Naples Italy 2009 - 2012 Scientific Director, Cancer Continuum, Illawarra Health and Medical Research Institute 2009 – Visiting Research Fellow, Finsen Laboratory, University of Copenhagen, Denmark 2006- Associate Professor, School of Biological Sciences, University of Wollongong 2005-2008 - Cancer Institute NSW Fellow (based at University of Wollongong) 2004 - Gessellschaft fur Biotechnologische Forschung (GBF) Fellow, Braunschweig, Germany 1998-2005 - Lecturer/Senior Lecturer, Department of Biological Sciences, University of Wollongong 1993-1997 - Research Fellow, Department Biological Sciences, University of Wollongong 1990-1992 - Fogarty Visiting Post-Doctoral Fellow, National Institutes of Health, Bethesda USA

Prof Ranson has an ongoing research interest in the cell and molecular biology of cancer migration, invasion and metastasis with a particular focus on the urokinase plasminogen activation system (PAS) and the putative protective role of its inhibitor SerpinB2 (PAI-2) in cancer. She also leads the pre-clinical development of targeted anti-cancer drugs, as well as improved delivery of chemotherapeutic drugs. Prof Ranson also contributes to research regarding streptococcal pathogenesis.

Lee JA, Yerbury JJ, Farrawell N, Shearer RF, Constantinescu P, Hatters DM, Schroder WA , Suhrbier A, Wilson MR, Saunders DN, Ranson M. (2015) SerpinB2 (PAI-2) Modulates Proteostasis via Binding Misfolded Proteins and Promotion of Cytoprotective Inclusion Formation. PLoS ONE 10(6): e0130136.doi:10.1371/journal.pone.0130136. Vine KL, Lobov S, Chandran VI, Harris NLE and Ranson M. (2015) Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery. Pharmaceutical Research, 32:1045-1054 Sanderson-Smith ML, Zhang Y, Ly D, Donahue D, Hollands A, Nizet V, Ranson M, Ploplis VA, Walker MJ, Castellino FJ. (2013) A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection. PLOS Pathogens. 9(7): e1003469. doi:10.1371/journal.ppat.1003469. Vine KL Chandran VI, Locke JM, Matesic L, Lee J, Skropeta D, Bremner JB and Ranson M. (2012) Targeting Urokinase and the Transferrin Receptor with Novel, Anti-Mitotic N-Alkylisatin Cytotoxin Conjugates Causes Selective Cancer Cell Death and Reduces Tumor Growth. Current Cancer Drug Targets. 12:64-73 Cochran BJ, Croucher DR, Lobov, S, Saunders DN and Ranson M. (2011) Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of serpinE1 and serpinB2 in cancer. Journal of Biological Chemistry. 286: 24467-24475. Matthews H, Ranson M and Kelso MJ. (2011) Anti-Tumour/Metastasis Effects of the Potassium-Sparing Diuretic Amiloride: An Orally Active Anti-Cancer Drug Waiting for its Call-of-Duty? International Journal of Cancer. 129, 2051–2061. Vine KL, Matesic L Locke JM, Ranson M and Skropeta D. Cytotoxic and Anticancer Activities of Isatin and its Derivatives: A Comprehensive Review from 2000-2008. (2009) Anticancer Agents in Medicinal Chemistry.9:397-414 Croucher DR, Saunders DN, Lobov S and Ranson M. (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nature Reviews Cancer. 8:535-545. Stutchbury TK, Al-ejeh F, Stillfried GE, Croucher DR, Andrews JA, Irving D, Links M and Ranson M. (2007) Preclinical evaluation of PAI-2-DTTA-213Bi (alpha-PAI-2) in an orthotopic murine xenogenic model of human breast carcinoma. Molecular Cancer Therapeutics. 6: 203-212.